Introduction: Double-filtration plasmapheresis (DFPP) is a semi-selective blood purification method based on dual filtration system. Regional citrate anticoagulation (RCA) is an appealing anticoagulation alternative in DFPP. However, there are still few reports on the safety of RCA in DFPP treatment. Objective: To investigate the anticoagulation effect and safety of RCA for DFPP in critical patients. Methods: A total of 34 critical patients treated with DFPP were retrospectively studied. The incidence of coagulation during extracorporeal circulation after single treatment was compared before and after treatment. Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, blood routine indexes, blood gas analysis, peripheral ionic calcium (iCa), total peripheral calcium (TCa), TCa/iCa, and complications before and after single treatment were compared. The changes of transmembrane pressure, pressure drop were measured, and the indexes of coagulation before and after treatment were compared. Results: The blood coagulation <III class in plasma separator and vein ampulla after single DFPP procedure were 96.00 and 94.00%, respectively. There were no statistically significant changes regarding above parameters before and after treatment, except PH, base excess (BE), bicarbonate (HCO3), and TCa. Compared with pretreatment levels, PH, BE, and HCO3 were significantly increased at 5 min and 6 h after treatment (p < 0.05) and restored to the pretreatment levels at 24 h after treatment (p > 0.05). Level of TCa was significantly decreased at 5 min after treatment (p < 0.05), but there was no statistically significant difference at 6 and 24 h (p > 0.05). No treatment-related serious complications were observed in any of the patients. Conclusions: For critical patients who underwent DFPP procedure, RCA is safety and had significant anticoagulation effects, which is worthy of clinical application.

1.
Marlu R, Malvezzi P, Seyve L, Jouve T, Maurizi J, Defendi F, et al. Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation.
Thromb Res
. 2018 Jun;166:113–21.
2.
Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.
J Clin Apher
. 2013 Jul;28(3):145–284.
3.
Vatazin AV, Zulkarnaev AB. The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients.
Ter Arkh
. 2018 Jun;90(6):22–7.
4.
Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study.
Hepatol Res
. 2006 Nov;36(3):167–75.
5.
Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis.
Clin Exp Nephrol
. 2014 Feb;18(1):41–9.
6.
Mineshima M. Double filtration plasmapheresis: determination of the optimal albumin concentration in the supplementation fluid.
Transfus Apheresis Sci
. 2017 Oct;56(5):654–6.
7.
Terman DS, Garcia-Rinaldi R, Dannemann B, Moore D, Crumb C, Tavel A, et al. Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus combination chemotherapeutic agents.
Clin Exp Immunol
. 1978 Oct;34(1):32–41.
8.
Yu X, Zhang L, Wang L, Lu W, Sun F, Xu P, et al. MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.
Clin Rheumatol
. 2018 Apr;37(4):917–25.
9.
Mineshima M, Akiba T. Double filtration plasmapheresis in critical care. Ther Apher. 2002 Jun;6(3):180–3.
10.
Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW, et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure.
PLoS One
. 2017 Aug;12(8):e0182134.
11.
Stucker F, Ponte B, Tataw J, Martin PY, Wozniak H, Pugin J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.
Crit Care
. 2015 Mar;19(1):91.
12.
Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload?
Crit Care
. 2017 Nov;21(1):281.
13.
Zhao S, Ou H, Peng Y, Liu Z, Yang M, Xiao X. [Role of local citrate anticoagulation in continuous blood purification to patients at high risk of bleeding in ICU].
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2016 Dec;41(12):1334–39.
14.
Yuan S, Qian Y, Tan D, Mo D, Li X. Therapeutic plasma exchange: a prospective randomized trial to evaluate 2 strategies in patients with liver failure.
Transfus Apher Sci
. 2018 Apr;57(2):253–58.
15.
Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults.
Crit Care Med
. 2015 Aug;43(8):1622–9.
16.
Buturovic-Ponikvar J. Is Regional Citrate Anticoagulation the Future of Hemodialysis?
Ther Apher Dial
. 2016 Jun;20(3):234–9.
17.
Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis.
Nephrol Dial Transplant
. 2006 Jan;21(1):153–9.
18.
Nelson ES, Mulugeta L, Myers JG. Microgravity-induced fluid shift and ophthalmic changes.
Life (Basel)
. 2014 Nov;4(4):621–65.
19.
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.
J Clin Apher
. 2016 Jun;31(3):149–62.
20.
Wang W, Liu S, Li P, Jiang Z. Study on the use of dual plasma exchange equipment based on AQUARIUS continuous renal replacement therapy equipment.
Medical Equipment.
2016;29(23):24–5.
21.
Liu DW, Yang RL, Chen XK, Wang X. [Critical blood purification: from concept to practice].
Zhonghua Yi Xue Za Zhi
. 2012 Dec;92(45):3169–71.
22.
Li L, Ji D. Continuous blood purification. Nanjing: southeast university press. 2004;213.
23.
Baldwin I, Fealy N, Carty P, Boyle M, Kim I, Bellomo R. Bubble chamber clotting during continuous renal replacement therapy: vertical versus horizontal blood flow entry.
Blood Purif
. 2012;34(3-4):213–8.
24.
Wang T, Xu B, Fan R, Liu Z, Gong D. Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
J Clin Lipidol
. 2016 May-Jun;10(3):646–9.
25.
Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI.
Clin J Am Soc Nephrol
. 2014 Dec;9(12):2173–88.
26.
Khadzhynov D, Dahlinger A, Schelter C, Peters H, Kindgen-Milles D, Budde K, et al. Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation.
Crit Care Med
. 2017 Sep;45(9):e941–6.
27.
Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation.
Intensive Care Med
. 1995 Jan;21(1):84–93.
28.
Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials.
Crit Care
. 2016 May;20(1):144.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.